Fenofibrate - A potential systemic treatment for diabetic retinopathy?

American Journal of Ophthalmology

Volumn 154, Issue 1, 2012, Pages 6-12

  Wong, Tien Yin ^a,b   Simó, Rafael ^c   Mitchell, Paul ^d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BLOOD RETINA BARRIER; CELL PROTECTION; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; HUMAN; INFLAMMATION; LASER COAGULATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; REVIEW; SYSTEMIC THERAPY; VITRECTOMY;

EID: 84862734043     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2012.03.013     Document Type: Article

References (48)

1. International Diabetes Federation. IDF Diabetes Atlas. 5th ed. Available at: http://www.idf.org/diabetesatlas/5e/the-global-burden. Accessed: December 1, 2011.
2. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376(9735):124-136.
3. Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 2006;141(3):446-455.
4. Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006;124(12):1754-1760. (Pubitemid 44920172)
5. Zavrelova H, Hoekstra T, Alssema M, et al. Progression and regression: distinct developmental patterns of diabetic retinopathy in patients with type 2 diabetes treated in the diabetes care system west-friesland, the Netherlands. Diabetes Care 2011;34(4):867-872.
6. Wong TY, Mwamburi M, Klein R, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009;32(12):2307-2313.
7. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA 2007;298(8):902-916. (Pubitemid 47311296)
8. Simó R, Herández C. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia 2008;51(9):1574-1580.
9. Simó R, Hernández C. Advances in medical treatment of diabetic retinopathy. Diabetes Care 2009;32(8):1556-1562.
10. Lim LS, Cheung CM, Mitchell P, Wong TY. Emerging evidence concerning systemic safety of anti-VEGF agents - should ophthalmologists be concerned? Am J Ophthalmol 2011;152(3):329-331.
11. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348(5):383-393. (Pubitemid 36159355)
12. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358(6):580-591. (Pubitemid 351214285)
13. The ACCORD Study Group and ACCORD Eye Study Group; Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363(3):233-244.
14. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-2559.
15. Patel A; ADVANCE Collaborative Group, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370(9590):829-840.
16. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317(7160):703-713.
17. Lim LS, Wong TY. Lipids and diabetic retinopathy. Expert Opin Biol Ther 2012;12(1):93-105.
18. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361(1):40 -51.
19. Chaturvedi N, Porta M, Klein R, et al DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent1) and progression (DIRECT-Protect1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008;372(9647):1394 -1402.
20. Sjølie AK, Klein R, Porta M, et al DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect2): a randomized placebo-controlled trial. Lancet 2008;372(9647):1385-1393.
21. Keech A, Simes RJ, Barter P, et al; FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366(9500):1849-1861.
22. Keech AC, Mitchell P, Summanen PA, et al; FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370(9600):1687-1697. (Pubitemid 350100775)
23. ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362(17):1563-1574.
24. Ting R-D, Keech AC, Drury PL, et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment. Diabetes Care 2012;35(2):218-225.
25. Ballantyne CM, Davidson MH. Possible differences between fibrates in pharmacokinetic interactions with statins. Arch Intern Med 2003;163(19):2394- 2395. (Pubitemid 37310202)
26. Bergman AJ, Murphy G, Burke J, et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004;44(9):1054-1062. (Pubitemid 39096820)
27. The Diabetic Retinopathy Clinical Research Network; Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117(6):1064 -1077.e35.
28. Rosenson RS. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther 2008;6(10):1319 -1330.
29. Leung H, Wang JJ, Rochtchina E, Wong TY, Klein R, Mitchell P. Dyslipidaemia and microvascular disease in the retina. Eye 2005;19(8):861- 868.
30. Staels B, Dallongeville J, Auwerx J, Schoojans K, Leitersdorf E, Fruchart JC. Mechanisms of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98(19):2088 -2093.
31. Sasongko MB, Wong TY, Nguyen TT, et al. Serum apolipoproteins AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids. Diabetes Care 2011;34(2):474-479.
32. Sasongko MB, Wong TY, Nguyen TT, Shaw JE, Jenkins AJ, Wang JJ. Novel versus traditional risk markers for diabetic retinopathy. Diabetologia 2012;55(3):666-670.
33. Simó R, Hernández C. Fenofibrate for diabetic retinopathy. Lancet 2007;370(9600):1667-1668. (Pubitemid 350100776)
34. García-Ramírez M, Canals F, Hernández C, et al. Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia 2007;50(6):1294-1303. (Pubitemid 46701542)
35. Simó R, García-Ramírez M, Higuera M, Hernández C. Apolipoprotein A1 is overexpressed in the retina of diabetic patients. Am J Ophthalmol 2009;147(2):319-325.
36. Arakawa R, Tamehiro N, Nishimaki-Mogami T, Ueda K, Yokoyama S. Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol 2005;25(6):1193-1197. (Pubitemid 40776608)
37. Kim J, Ahn JH, Kim JH, et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 2007;84(5):886-893. (Pubitemid 46590130)
38. Miranda S, González-Rodríguez, García- Ramírez, et al. Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions. J Cell Physiol 2012;227(6):2352-2356.
39. Cheung N, Wong TY. Fenofibrate and diabetic retinopathy. Lancet 2008;371(9614):721-722. (Pubitemid 351288864)
40. Bordet R, Ouk T, Petrault O, et al. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 2006;34(Pt 6):1341-1346. (Pubitemid 46769051)
41. Villarroel M, Garcia-Ramírez M, Corraliza L, Hernández C, Simó R. Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation. Diabetologia 2011;54(6):1543-1553.
42. Trudeau K, Roy S, Guo W, et al. Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability. Invest Ophthalmol Vis Sci 2011;52(9):6348-6354.
43. Meissner M, Stein M, Urbich C, et al. PPAR αactivators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ Res 2004;94(3):324 -332.
44. Varet J, Vincent L, Mirshahi P, et al. Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci 2003;60(4):810-819. (Pubitemid 36570772)
45. Lim LS, Wong TY. Fibrate use in the United States and Canada. JAMA 2011;306(2):157-158; author reply 158-159.
46. Javitt JC. Cost savings associated with detection and treatment of diabetic eye disease. Pharmacoeconomics 1995;8(Suppl 1):33-39.
47. Pelletier EM, Shim B, Ben-Joseph R, Caro JJ. Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis. Pharmacoeconomics 2009;27(6):479-490.
48. Heintz E, Wiréhn AB, Peebo BB, Rosenqvist U, Levin LA. Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden. Diabetologia 2010;53(10):2147-2154.